Global R&D Pipeline
My Favorite
Hot Targets:
CTLA-4
Back
Total number of drugs
172
Phase II and later clinical stages
18%
Involving companies
280
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tremelimumab | Tremelimumab | Monoclonal antibody | Neoplasms Digestive System Disorders Respiratory Diseases Urogenital Diseases Immune System Diseases Infectious Diseases Nervous System Diseases Endocrinology and Metabolic Disease Hemic and Lymphatic Diseases Mouth and Tooth Diseases Otorhinolaryngologic Diseases Skin and Musculoskeletal Diseases Other Diseases | CTLA4 inhibitors | AstraZeneca AB Pfizer Inc. | AstraZeneca PLC MedImmune LLC Boehringer Ingelheim Pharma GmbH & Co., KG AstraZeneca Investment (China) Co. Ltd. AstraZeneca Pty Ltd. 阿斯利康全球研发（中国）有限公司 Exelixis, Inc. AstraZeneca AB Laboratoire Pierre Fabre Oncologie AstraZeneca KK Astrazeneca Korea Ltd. Vetter Pharma-Fertigung GmbH & Co. KG AstraZeneca Canada, Inc. | Approved | NDA/BLA | United States European Union Japan Canada Australia Iceland South Korea Liechtenstein Norway | 2022-10-21 | - | Orphan Drug（European Union） Orphan Drug（United States） Priority Review（United States） | - | - | - | - | Tremelimumab | - | - | detail > | |
| Iparomlimab/Tuvonralimab | Iparomlimab/Tuvonralimab | Bispecific antibody | Neoplasms Urogenital Diseases Digestive System Disorders Mouth and Tooth Diseases Otorhinolaryngologic Diseases Respiratory Diseases Other Diseases Skin and Musculoskeletal Diseases | CTLA4 inhibitors PD-1 inhibitors | Qilu Pharmaceutical Co., Ltd. | Qilu Pharmaceutical Co., Ltd. | Approved | Approved | China | 2024-09-26 | 2024-09-26 | Conditional marketing approval（China） | - | - | - | - | Iparomlimab/Tuvonralimab | - | - | detail > | |
| Quavonlimab | Quavonlimab | Monoclonal antibody | Neoplasms Urogenital Diseases Respiratory Diseases Skin and Musculoskeletal Diseases | CTLA4 inhibitors | Merck Sharp & Dohme Corp. | Merck Sharp & Dohme Corp. Akeso Biopharma Co., Ltd. | Phase 3 | Phase 1/2 | - | - | - | - | - | - | - | - | Quavonlimab | - | - | detail > | |
| Gotistobart | Gotistobart | Monoclonal antibody | Neoplasms Respiratory Diseases Digestive System Disorders Endocrinology and Metabolic Disease Urogenital Diseases Mouth and Tooth Diseases Skin and Musculoskeletal Diseases Other Diseases | CTLA4 inhibitors | OncoImmune, Inc. | Guangzhou Angke Immune Biotechnology Co., Ltd OncoC4, Inc. BioNTech SE | Phase 3 | Phase 3 | - | - | - | Breakthrough Therapy（China） Fast Track（United States） Orphan Drug（United States） | - | - | - | - | Gotistobart | - | - | detail > | |
| Botensilimab | Botensilimab | Monoclonal antibody | Neoplasms Digestive System Disorders Nervous System Diseases Endocrinology and Metabolic Disease Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases | CTLA4 inhibitors | Agenus, Inc. | City of Hope National Medical Center Agenus, Inc. University of Southern California | Phase 3 | - | - | - | - | Fast Track（United States） | - | - | - | - | Botensilimab | - | - | detail > | |
| Ipilimumab | Ipilimumab | Monoclonal antibody | Neoplasms Digestive System Disorders Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases Nervous System Diseases Congenital Disorders Immune System Diseases Infectious Diseases Endocrinology and Metabolic Disease Eye Diseases Hemic and Lymphatic Diseases Mouth and Tooth Diseases Otorhinolaryngologic Diseases | CTLA4 inhibitors | Bristol Myers Squibb Co. | The Sidney Kimmel Comprehensive Cancer Center Bristol Myers Squibb Co. Bristol-Myers Squibb Pharma EEIG National Cancer Institute The University of Texas MD Anderson Cancer Center City of Hope National Medical Center Mayo Clinic Ono Pharmaceutical Co., Ltd. Bristol-Myers Squibb KK Sarcoma Oncology Center Stanford University Bristol-Myers Squibb Australia Pty Ltd. Dana-Farber Cancer Institute, Inc. Emory University Regeneron Pharmaceuticals, Inc. Universitair Ziekenhuis Brussel Sino-American Shanghai Squibb Pharmaceuticals Ltd. University of Utah University of California San Diego | Approved | Approved | United States China European Union Japan Australia Iceland South Korea Liechtenstein Norway | 2011-03-25 | 2021-06-08 | Accelerated Approval（United States） Breakthrough Therapy（China） Breakthrough Therapy（United States） Fast Track（United States） Orphan Drug（South Korea） Orphan Drug（United States） Priority Review（Australia） Priority Review（China） Priority Review（United States） Conditional marketing approval（China） Orphan Drug（Japan） | - | - | - | - | Ipilimumab | - | - | detail > | |
| Pembrolizumab/Quavonlimab | Pembrolizumab/Quavonlimab | Monoclonal antibody | Neoplasms Urogenital Diseases Digestive System Disorders Respiratory Diseases Skin and Musculoskeletal Diseases | CTLA4 inhibitors PD-1 inhibitors | Merck Sharp & Dohme Corp. | Merck Sharp & Dohme Corp. MSD R&D (China) Co. Ltd. Merck Sharp & Dohme LLC | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | Pembrolizumab/Quavonlimab | - | - | detail > | |
| Cadonilimab | Cadonilimab | Bispecific antibody | Neoplasms Digestive System Disorders Urogenital Diseases Respiratory Diseases Endocrinology and Metabolic Disease Mouth and Tooth Diseases Otorhinolaryngologic Diseases Other Diseases Immune System Diseases Hemic and Lymphatic Diseases | CTLA4 inhibitors PD-1 inhibitors | Akeso Biopharma Co., Ltd. | Akeso Biopharma Co., Ltd. Shenzhen Chipscreen Biosciences Co., Ltd. Akeso Pharmaceuticals, Inc. West China Hospital | Approved | Approved | China | 2022-06-28 | 2022-06-28 | Breakthrough Therapy（China） Fast Track（United States） Orphan Drug（United States） Priority Review（China） Conditional marketing approval（China） | - | - | - | - | Cadonilimab | - | - | detail > | |
| Volrustomig | Volrustomig | Bispecific antibody | Neoplasms Respiratory Diseases Urogenital Diseases Other Diseases Digestive System Disorders Skin and Musculoskeletal Diseases | CTLA4 inhibitors PD-1 inhibitors | MedImmune LLC | AstraZeneca PLC AstraZeneca Nijmegen BV 阿斯利康全球研发（中国）有限公司 AstraZeneca AB MedImmune LLC Institut Bergonié | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | Volrustomig | - | - | detail > | |
| Erfonrilimab | Erfonrilimab | Bispecific antibody | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Respiratory Diseases Other Diseases Urogenital Diseases | CTLA4 inhibitors PDL1 inhibitors | Suzhou Alphamab Co., Ltd. | Beijing Institute for Cancer Research Inxmed (Shanghai) Co., Ltd Jiangsu Alphamab Biopharmaceuticals Co., Ltd Suzhou Kintor Pharmaceuticals, Inc. | Phase 3 | Phase 3 | - | - | - | Orphan Drug（United States） Special Review Project（China） | - | - | - | - | Erfonrilimab | - | - | detail > |
Total 172 data
1
2
3
4
5
6
...
17
18
